Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 7/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.53 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 4/20 | 0.34 |
| ▸ | MAOB | P27338 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22310734 | 0.90 | MET (0.43) | METNQO2DGAT1KITMAOA | |
| SCHEMBL22310300 | 0.90 | MET (0.63) | METNQO2CXCR1DGAT1MAOA | |
| SCHEMBL22310378 | 0.87 | MET (0.44) | METNQO2DGAT1ACHEMAOA | |
| SCHEMBL22310732 | 0.81 | MET (0.52) | METNQO2MAOB | |
| SCHEMBL22310322 | 0.79 | MET (0.39) | METNQO2ACHEMAOB | |
| SCHEMBL22310306 | 0.79 | MET (0.57) | METNQO2CXCR1DGAT1 | |
| SCHEMBL22309774 | 0.79 | MET (0.51) | METNQO2DGAT1MAOB | |
| SCHEMBL22309742 | 0.77 | MET (0.40) | METNQO2DGAT1ACHE | |
| SCHEMBL22309704 | 0.75 | MET (0.63) | METNQO2PDE2AMAOAMAOB | |
| SCHEMBL1300844 | 0.74 | MET (0.51) | METNQO2CXCR1HRH3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020156453-A1 | PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR | 南京明德新药研发有限公司 | 2020-08-06 | — | — | WO | disclosed |